

# Olanzapine

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878  
Issue date: 03/04/2023 Version: 1.0

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1. Product identifier

Product form : Substance  
Substance name : Olanzapine  
Product code : 201600655  
Synonyms : Olanzapine, salts, hydrates, isomers and impurities where applicable

#### 1.2. Relevant identified uses of the substance or mixture and uses advised against

##### 1.2.1. Relevant identified uses

Main use category : The product is intended for research, analysis and scientific education.  
Use of the substance/mixture : For professional use only  
Function or use category : Laboratory chemicals

##### 1.2.2. Uses advised against

Restrictions on use : Do not use : Ingestion, Inhalation, Dermal

#### 1.3. Details of the supplier of the safety data sheet

European Directorate for the Quality of Medicines & Healthcare  
EDQM, Council of Europe 7, Allée Kastner, CS30026  
F- 67081 Strasbourg  
France  
T +33(0)388412035 - F +33(0)388412771  
[sds@edqm.eu](mailto:sds@edqm.eu) - [www.edqm.eu](http://www.edqm.eu)

#### 1.4. Emergency telephone number

Emergency number : +33(0)390215608

### SECTION 2: Hazards identification

#### 2.1. Classification of the substance or mixture

##### Classification according to Regulation (EC) No. 1272/2008 [CLP]

Acute toxicity (oral), Category 3	H301
Skin sensitisation, Category 1	H317
Reproductive toxicity, Additional category, Effects on or via lactation	H362
Specific target organ toxicity – Single exposure, Category 3, Narcosis	H336
Specific target organ toxicity – Repeated exposure, Category 2	H373
Full text of H- and EUH-statements: see section 16	

##### Adverse physicochemical, human health and environmental effects

Expert judgement and weight of evidence determination.

#### 2.2. Label elements

##### Labelling according to Regulation (EC) No. 1272/2008 [CLP]

Hazard pictograms (CLP) :



GHS06

GHS08

Signal word (CLP) : Danger  
Hazard statements (CLP) :  
H301 - Toxic if swallowed.  
H317 - May cause an allergic skin reaction.  
H336 - May cause drowsiness or dizziness.  
H362 - May cause harm to breast-fed children.  
H373 - May cause damage to organs through prolonged or repeated exposure.

# Olanzapine

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### Precautionary statements (CLP)

: P201 - Obtain special instructions before use.  
P260 - Do not breathe dust/fume/gas/mist/vapours/spray.  
P263 - Avoid contact during pregnancy and while nursing.  
P264 - Wash hands, forearms and face thoroughly after handling.  
P270 - Do not eat, drink or smoke when using this product.  
P271 - Use only outdoors or in a well-ventilated area.  
P272 - Contaminated work clothing should not be allowed out of the workplace.  
P280 - Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.  
P301+P310 - IF SWALLOWED: Immediately call a POISON CENTER or doctor.  
P302+P352 - IF ON SKIN: Wash with plenty of water.  
P304+P340 - IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
P308+P313 - IF exposed or concerned: Get medical advice/attention.  
P312 - Call a POISON CENTRE or doctor if you feel unwell.  
P321 - Specific treatment (see supplemental first aid instruction on this label).  
P330 - Rinse mouth.  
P333+P313 - If skin irritation or rash occurs: Get medical advice/attention.  
P362+P364 - Take off contaminated clothing and wash it before reuse.  
P403+P233 - Store in a well-ventilated place. Keep container tightly closed.  
P405 - Store locked up.  
P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation.

Labelling according to: exemption for inner packaging where the contents do not exceed 10ml

### Hazard pictograms (CLP)



### 2.3. Other hazards

No additional information available

## SECTION 3: Composition/information on ingredients

### 3.1. Substances

Name	Product identifier	%	Classification according to Regulation (EC) No. 1272/2008 [CLP]
Olanzapine	-	≤ 100	Acute Tox. 3 (Oral), H301 (ATE=100 mg/kg bodyweight) Skin Sens. 1, H317 Lact., H362 STOT SE 3, H336 STOT RE 2, H373

Full text of H- and EUH-statements: see section 16

### 3.2. Mixtures

Not applicable

## SECTION 4: First aid measures

### 4.1. Description of first aid measures

First-aid measures after inhalation : Move to fresh air. Allow affected person to breathe fresh air.  
First-aid measures after skin contact : Wipe off as much as possible (using a clean, soft, absorbent material). Wash with plenty of water and detergent.

# Olanzapine

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

First-aid measures after eye contact	: Rinse with water while holding the eyes wide open.
First-aid measures after ingestion	: Rinse mouth. Immediately call a POISON CENTER/doctor. Prolonged medical observation may be indicated.

### 4.2. Most important symptoms and effects, both acute and delayed

Symptoms/effects	: Delayed adverse effects possible.
Symptoms/effects after inhalation	: Insufficient data available.
Symptoms/effects after skin contact	: Insufficient data available.
Symptoms/effects after eye contact	: Insufficient data available.

### 4.3. Indication of any immediate medical attention and special treatment needed

Get medical advice/attention. If possible show this sheet, if not available show packaging or label.

## SECTION 5: Firefighting measures

### 5.1. Extinguishing media

Suitable extinguishing media	: Extinguishing blanket.
------------------------------	--------------------------

### 5.2. Special hazards arising from the substance or mixture

Fire hazard	: See Heading 2.2.
-------------	--------------------

### 5.3. Advice for firefighters

Firefighting instructions	: Use extinguishing media appropriate for surrounding fire.
---------------------------	---

## SECTION 6: Accidental release measures

### 6.1. Personal precautions, protective equipment and emergency procedures

General measures	: Avoid any direct contact with the product. Do not breathe dust/fume/gas/mist/vapours/spray.
------------------	---

#### 6.1.1. For non-emergency personnel

Emergency procedures	: Wear suitable protective clothing, gloves and eye or face protection.
----------------------	---

#### 6.1.2. For emergency responders

No additional information available

### 6.2. Environmental precautions

No additional information available

### 6.3. Methods and material for containment and cleaning up

Methods for cleaning up	: Ensure waste is collected and contained. Clean thoroughly. Wash the non-recoverable remainder with : Sodium hypochlorite solution.
-------------------------	--

### 6.4. Reference to other sections

No additional information available

## SECTION 7: Handling and storage

### 7.1. Precautions for safe handling

Additional hazards when processed	: The attention of the user is drawn to the risks possibly incurred by using the product for any other purpose than that for which it was intended.
Precautions for safe handling	: Material should be handled with caution. Avoid any direct contact with the product. Material should be handled in a laboratory hood whenever possible.
Hygiene measures	: Handle in accordance with good industrial hygiene and safety procedures.

# Olanzapine

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### 7.2. Conditions for safe storage, including any incompatibilities

Technical measures : Comply with applicable regulations.  
Storage conditions : Store locked up.

### 7.3. Specific end use(s)

See Heading 1.

## SECTION 8: Exposure controls/personal protection

### 8.1. Control parameters

#### 8.1.1 National occupational exposure and biological limit values

No additional information available

#### 8.1.2. Recommended monitoring procedures

No additional information available

#### 8.1.3. Air contaminants formed

No additional information available

#### 8.1.4. DNEL and PNEC

No additional information available

#### 8.1.5. Control banding

No additional information available

### 8.2. Exposure controls

#### 8.2.1. Appropriate engineering controls

##### Appropriate engineering controls:

Keep in a well-ventilated room. Use only in a exhaust booth with integrated air filter. High efficiency particulate air filter (HEPA filter).

#### 8.2.2. Personal protection equipment

##### 8.2.2.1. Eye and face protection

##### Eye protection:

Safety glasses. DIN EN 166

##### 8.2.2.2. Skin protection

##### Skin and body protection:

Use chemically protective clothing. DIN EN 13034

##### Hand protection:

Chemically resistant protective gloves. ISO 374-1

##### 8.2.2.3. Respiratory protection

##### Respiratory protection:

Dust production: dust mask with filter type P3. DIN EN 140 & 149. Liquid product : Aerosol mask. Wear breathing apparatus if exposed to vapours/dusts/aerosols

##### 8.2.2.4. Thermal hazards

No additional information available

#### 8.2.3. Environmental exposure controls

No additional information available

## SECTION 9: Physical and chemical properties

### 9.1. Information on basic physical and chemical properties

Physical state : Solid

# Olanzapine

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

Colour	: Not available
Appearance	: Powder.
Odour	: Not applicable.
Odour threshold	: Not available
Melting point	: Not available
Freezing point	: Not available
Boiling point	: Not available
Flammability	: Not available
Explosive limits	: Not applicable
Lower explosion limit	: Not applicable
Upper explosion limit	: Not applicable
Flash point	: Not applicable
Auto-ignition temperature	: Not applicable
Decomposition temperature	: Not available
pH	: Not available
pH solution	: Not available
Viscosity, kinematic	: Not applicable
Solubility	: Water: < 0.1 g/l
Partition coefficient n-octanol/water (Log Kow)	: Not available
Vapour pressure	: Not available
Vapour pressure at 50°C	: Not available
Density	: Not available
Relative density	: Not available
Relative vapour density at 20°C	: Not applicable
Particle size	: Not available

### 9.2. Other information

#### 9.2.1. Information with regard to physical hazard classes

No additional information available

#### 9.2.2. Other safety characteristics

No additional information available

## SECTION 10: Stability and reactivity

### 10.1. Reactivity

Stable under normal conditions.

### 10.2. Chemical stability

No additional information available

### 10.3. Possibility of hazardous reactions

No additional information available

### 10.4. Conditions to avoid

No additional information available

### 10.5. Incompatible materials

None under normal use. See Section 7.

### 10.6. Hazardous decomposition products

When heated to decomposition, emits dangerous fumes.

## SECTION 11: Toxicological information

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute toxicity (oral) : Toxic if swallowed.

# Olanzapine

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

Acute toxicity (dermal)	: Not classified
Acute toxicity (inhalation)	: Not classified
Skin corrosion/irritation	: Not classified
Serious eye damage/irritation	: Not classified (Conclusive but not sufficient for classification)
Respiratory or skin sensitisation	: May cause an allergic skin reaction.
Germ cell mutagenicity	: Not classified
Carcinogenicity	: Not classified
Reproductive toxicity	: May cause harm to breast-fed children.
STOT-single exposure	: May cause drowsiness or dizziness.
STOT-repeated exposure	: May cause damage to organs through prolonged or repeated exposure.
Aspiration hazard	: Not classified

### 11.2. Information on other hazards

No additional information available

## SECTION 12: Ecological information

### 12.1. Toxicity

Ecology - general	: Hazardous waste. Use suitable disposal containers.
Hazardous to the aquatic environment, short-term (acute)	: Not classified
Hazardous to the aquatic environment, long-term (chronic)	: Not classified

### 12.2. Persistence and degradability

No additional information available

### 12.3. Bioaccumulative potential

No additional information available

### 12.4. Mobility in soil

No additional information available

### 12.5. Results of PBT and vPvB assessment

No additional information available

### 12.6. Endocrine disrupting properties

No additional information available

### 12.7. Other adverse effects

No additional information available

## SECTION 13: Disposal considerations

### 13.1. Waste treatment methods

Regional legislation (waste)	: Dispose in a safe manner in accordance with local/national regulations.
Product/Packaging disposal recommendations	: Do not empty into drains, dispose of this material and its container at hazardous or special waste collection point.




## SECTION 14: Transport information

In accordance with ADR / IMDG / IATA

# Olanzapine

## Safety Data Sheet


according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

ADR	IMDG	IATA
<b>14.1. UN number or ID number</b>		
UN 2811	UN 2811	UN 2811
<b>14.2. UN proper shipping name</b>		
TOXIC SOLID, ORGANIC, N.O.S.	TOXIC SOLID, ORGANIC, N.O.S.	Toxic solid, organic, n.o.s.
<b>Transport document description</b>		
UN 2811 TOXIC SOLID, ORGANIC, N.O.S., 6.1, III, (E)	UN 2811 TOXIC SOLID, ORGANIC, N.O.S., 6.1, III	UN 2811 Toxic solid, organic, n.o.s., 6.1, III
<b>14.3. Transport hazard class(es)</b>		
6.1	6.1	6.1
		
<b>14.4. Packing group</b>		
III	III	III
<b>14.5. Environmental hazards</b>		
Dangerous for the environment: No	Dangerous for the environment: No Marine pollutant: No	Dangerous for the environment: No
No supplementary information available		

### 14.6. Special precautions for user

#### Overland transport

Classification code (ADR) : T2  
Special provisions (ADR) : 274, 614  
Limited quantities (ADR) : 5kg  
Excepted quantities (ADR) : E1  
Packing instructions (ADR) : P002, IBC08, LP02, R001  
Special packing provisions (ADR) : B3  
Mixed packing provisions (ADR) : MP10  
Portable tank and bulk container instructions (ADR) : T1  
Portable tank and bulk container special provisions (ADR) : TP33  
Tank code (ADR) : SGAH, L4BH  
Tank special provisions (ADR) : TU15, TE19  
Vehicle for tank carriage : AT  
Transport category (ADR) : 2  
Special provisions for carriage - Bulk (ADR) : VC1, VC2, AP7  
Special provisions for carriage - Loading, unloading and handling (ADR) : CV13, CV28  
Special provisions for carriage - Operation (ADR) : S9  
Hazard identification number (Kemler No.) : 60  
Orange plates :



Tunnel restriction code (ADR) : E

#### Transport by sea

Special provisions (IMDG) : 223, 274  
Limited quantities (IMDG) : 5 kg  
Excepted quantities (IMDG) : E1

# Olanzapine

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

Packing instructions (IMDG)	: P002
IBC packing instructions (IMDG)	: IBC08
IBC special provisions (IMDG)	: B3
Tank instructions (IMDG)	: T1
Tank special provisions (IMDG)	: TP33
EmS-No. (Fire)	: F-A
EmS-No. (Spillage)	: S-A
Stowage category (IMDG)	: A
Properties and observations (IMDG)	: Toxic if swallowed, by skin contact or by inhalation.

### Air transport

PCA Excepted quantities (IATA)	: E1
PCA Limited quantities (IATA)	: Y645
PCA limited quantity max net quantity (IATA)	: 10kg
PCA packing instructions (IATA)	: 670
PCA max net quantity (IATA)	: 100kg
CAO packing instructions (IATA)	: 677
CAO max net quantity (IATA)	: 200kg
Special provisions (IATA)	: A3, A5
ERG code (IATA)	: 6L

### 14.7. Maritime transport in bulk according to IMO instruments

Not applicable

## SECTION 15: Regulatory information

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### 15.1.1. EU-Regulations

##### REACH Annex XVII (Restriction List)

Not listed on REACH Annex XVII

##### REACH Annex XIV (Authorisation List)

Not listed on REACH Annex XIV (Authorisation List)

##### REACH Candidate List (SVHC)

Not listed on the REACH Candidate List

##### PIC Regulation (Prior Informed Consent)

Not applicable.

##### POP Regulation (Persistent Organic Pollutants)

Not applicable.

##### Ozone Regulation (1005/2009)

Not listed on the Ozone Depletion list (Regulation EU 1005/2009)

##### Explosives Precursors Regulation (2019/1148)

Contains no substance(s) listed on the Explosives Precursors list (Regulation EU 2019/1148 on the marketing and use of explosives precursors)

##### Drug Precursors Regulation (273/2004)

Contains no substance(s) listed on the Drug Precursors list (Regulation EC 273/2004 on the manufacture and the placing on market of certain substances used in the illicit manufacture of narcotic drugs and psychotropic substances)

#### 15.1.2. National regulations

No additional information available

### 15.2. Chemical safety assessment

No additional information available



# Olanzapine

## Safety Data Sheet

according to the REACH Regulation (EC) 1907/2006 amended by Regulation (EU) 2020/878

### SECTION 16: Other information

#### Indication of changes:

Classification of the substance or mixture.

#### Full text of H- and EUH-statements:

Acute Tox. 3 (Oral)	Acute toxicity (oral), Category 3
H301	Toxic if swallowed.
H317	May cause an allergic skin reaction.
H336	May cause drowsiness or dizziness.
H362	May cause harm to breast-fed children.
H373	May cause damage to organs through prolonged or repeated exposure.
Lact.	Reproductive toxicity, Additional category, Effects on or via lactation
Skin Sens. 1	Skin sensitisation, Category 1
STOT RE 2	Specific target organ toxicity – Repeated exposure, Category 2
STOT SE 3	Specific target organ toxicity – Single exposure, Category 3, Narcosis

Safety Data Sheet (SDS), EU

**DISCLAIMER OF LIABILITY** The EDQM has created this SDS as a downstream user for regulatory compliance to rules applicable to chemicals only. This article is intended only for small-volume laboratory analysis and other routine testing prescribed in the pharmacopoeia or EDQM study protocol, under controlled conditions and by professionals only. Any other use of this article or the SDS information is the sole responsibility of the user. This substance is present in articles in quantities totalling under 10 kg per year. There is no human or environmental exposure under intended and foreseeable conditions of use. The user has the responsibility for handling, storage, use conditions and disposal of this article and for any use of the information in this SDS. The information has been obtained from suppliers and is without any warranty, express or implied, regarding its correctness. For this and other reasons, we do not assume responsibility and expressly disclaim liability for loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of the article.